Evidence map›Paper›PMID 39487762›Full record

ArticlemAbs

Understanding the impacts of dual methionine oxidations in complementarity-determining regions on the structure of monoclonal antibodies.

Bo Zhao, Joy Yoon, Bojie Zhang, Youmi Moon, Yue Fu, Yinyin Li, Yunlong Zhao, Hui Xiao, Ning Li

Abstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bo ZhaoAnalytical Chemistry, Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.ORCID 0000-0002-1882-3182
Joy YoonAnalytical Chemistry, Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.
Bojie ZhangBioanalytical and Biomarker Technologies, Therapeutic Proteins Department, Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.
Youmi MoonProtein Biochemistry Group, Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
Yue FuProtein Biochemistry Group, Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
Yinyin LiBioanalytical and Biomarker Technologies, Therapeutic Proteins Department, Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.
Yunlong ZhaoAnalytical Chemistry, Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.ORCID 0000-0001-9832-1694
Hui XiaoAnalytical Chemistry, Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.ORCID 0000-0001-9489-054X
Ning LiAnalytical Chemistry, Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methionine oxidation can substantially alter the structure and functionality of monoclonal antibodies (mAbs), especially when it occurs in the complementarity-determining regions (CDRs). It is imperative to fully understand the effects of methionine oxidation because these modifications can affect the binding affinity, stability, and immunogenicity of mAbs. Moreover, the presence of multiple methionines in close proximity within the amino acid sequence increases the complexity of accurate characterization, and sophisticated analytical methods are required to detect these modifications. In this study, we used hydrogen deuterium exchange mass spectrometry (HDX-MS) and homology modeling to investigate the effects of dual methionine oxidations (heavy chain (HC) Met111 and Met115) within a single CDR on the structure of a mAb. Our findings reveal that the solvent-accessible methionine (HC Met111) is more prone to oxidation, but such a modification does not result in conformational changes in the mAb. In contrast, the methionine (HC Met115) at the V

Indexed as

Antibodies, MonoclonalComplementarity Determining RegionsMethionineOxidation-ReductionHumansAntibodies, MonoclonalComplementarity Determining RegionsMethionineAntibody higher order structureAntigen bindingComplementarity determining regionHDX-MShomology modelingMethionine oxidationStereochemistry

Identifiers

PMID39487762
PMCPMC11540082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.